This test builds on the Patient Health Questionnaire — 9 items (PHQ-9), published in 2001 by Kroenke, Spitzer and Williams in the Journal of General Internal Medicine. Each of its 9 items maps to one DSM-5-TR criterion for a major depressive episode (APA, 2022), anchored to a 2-week recall window.
Beyond the PHQ-9, you answer a short context chapter (age, life situation, symptom duration, history) and a differential chapter that explores other possible leads — anxiety, bipolar, burnout, borderline. You gain precision: your report tells apart what really looks like depression from what may come from somewhere else.
Why this differential? Because a high depression score can mask a different clinical picture — notably a depressive episode in a bipolar context, where treatment diverges sharply (Ghaemi et al., 2003). A useful screening tool must be able to point you toward the right specialist if your profile looks more like something else than unipolar depression.
A few numbers for context: depression affects 15–20 % of the population over a lifetime (Inserm), and around 10 % of adults 18–75 over 12 months (Baromètre Santé 2017). The PHQ-9 shows a sensitivity of about 88 % and a specificity of about 88 % at the ≥ 10 cutoff (meta-analysis Manea et al., 2012, CMAJ, 18 studies). It is the screening instrument recommended by primary-care bodies worldwide and used by clinicians to monitor treatment response.